Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
BGMD's Cash to Debt is ranked higher than
91% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.62 vs. BGMD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
BGMD' s Cash to Debt Range Over the Past 10 Years
Min: 0.23  Med: 1.39 Max: No Debt
Current: No Debt
Equity to Asset -0.93
BGMD's Equity to Asset is ranked lower than
95% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BGMD: -0.93 )
Ranked among companies with meaningful Equity to Asset only.
BGMD' s Equity to Asset Range Over the Past 10 Years
Min: -11.02  Med: -1.40 Max: 0.8
Current: -0.93
-11.02
0.8
F-Score: 5
Z-Score: -115.62
M-Score: -4.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -295.59
BGMD's Operating margin (%) is ranked lower than
82% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.72 vs. BGMD: -295.59 )
Ranked among companies with meaningful Operating margin (%) only.
BGMD' s Operating margin (%) Range Over the Past 10 Years
Min: -1783.39  Med: -324.29 Max: -69.34
Current: -295.59
-1783.39
-69.34
Net-margin (%) -338.57
BGMD's Net-margin (%) is ranked lower than
84% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. BGMD: -338.57 )
Ranked among companies with meaningful Net-margin (%) only.
BGMD' s Net-margin (%) Range Over the Past 10 Years
Min: -2095.48  Med: -363.88 Max: -78.43
Current: -338.57
-2095.48
-78.43
ROA (%) -180.66
BGMD's ROA (%) is ranked lower than
95% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. BGMD: -180.66 )
Ranked among companies with meaningful ROA (%) only.
BGMD' s ROA (%) Range Over the Past 10 Years
Min: -174.66  Med: -112.78 Max: -67.46
Current: -180.66
-174.66
-67.46
ROC (Joel Greenblatt) (%) -9777.57
BGMD's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -12.38 vs. BGMD: -9777.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BGMD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -9110.84  Med: -2838.41 Max: -327.37
Current: -9777.57
-9110.84
-327.37
Revenue Growth (3Y)(%) -33.60
BGMD's Revenue Growth (3Y)(%) is ranked lower than
87% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.10 vs. BGMD: -33.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BGMD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -31.80 Max: -2.8
Current: -33.6
EBITDA Growth (3Y)(%) -50.90
BGMD's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. BGMD: -50.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BGMD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -25.70 Max: -38.9
Current: -50.9
EPS Growth (3Y)(%) -46.60
BGMD's EPS Growth (3Y)(%) is ranked lower than
89% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. BGMD: -46.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BGMD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -27.15 Max: -37.2
Current: -46.6
» BGMD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-19)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with BGMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:OTCPK:DIGP, OTCPK:ABMC, OTCPK:MTST, OTCPK:ETAH, OTCPK:IDYLD, OTCPK:IMEXF, OTCPK:PSIDD, OTCPK:CNSO, OTCPK:MEDD, OTCPK:CGNH, OTCPK:JFIL, OTCPK:EXDI, NAS:CBMX, OTCPK:MCUIF, OTCPK:BMKDF, OTCPK:DDXSQ, NAS:SGNL, OTCPK:MNLIF, OTCPK:GNWSF, OTCPK:OXIS » details
Traded in other countries:RBM1.Germany,
BG Medicine Inc is engaged in developing and commercializing diagnostic products that may be used to help guide the care and management of patients who suffer from heart failure and related disorders. Its product includes BGM Galectin-3 test.

BG Medicine is a life sciences company engaged into discovery, development, and commercialization of novel diagnostic tests based on biomarkers. Its tests include BGM Galectin-3, CardioSCORE.

Ratios

vs
industry
vs
history
P/S 1.16
BGMD's P/S is ranked higher than
81% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. BGMD: 1.16 )
Ranked among companies with meaningful P/S only.
BGMD' s P/S Range Over the Past 10 Years
Min: 0.98  Med: 9.28 Max: 109.58
Current: 1.16
0.98
109.58
EV-to-EBIT -0.15
BGMD's EV-to-EBIT is ranked lower than
99.99% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. BGMD: -0.15 )
Ranked among companies with meaningful EV-to-EBIT only.
BGMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.2  Med: -2.35 Max: -0.1
Current: -0.15
-9.2
-0.1
EV-to-EBITDA -0.15
BGMD's EV-to-EBITDA is ranked lower than
99.99% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.01 vs. BGMD: -0.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
BGMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.6  Med: -2.40 Max: -0.1
Current: -0.15
-9.6
-0.1
Current Ratio 1.65
BGMD's Current Ratio is ranked lower than
73% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.89 vs. BGMD: 1.65 )
Ranked among companies with meaningful Current Ratio only.
BGMD' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 1.20 Max: 4.87
Current: 1.65
0.2
4.87
Quick Ratio 1.53
BGMD's Quick Ratio is ranked lower than
70% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. BGMD: 1.53 )
Ranked among companies with meaningful Quick Ratio only.
BGMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 1.14 Max: 4.82
Current: 1.53
0.2
4.82
Days Inventory 194.47
BGMD's Days Inventory is ranked lower than
85% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.32 vs. BGMD: 194.47 )
Ranked among companies with meaningful Days Inventory only.
BGMD' s Days Inventory Range Over the Past 10 Years
Min: 62.5  Med: 125.67 Max: 196.96
Current: 194.47
62.5
196.96
Days Sales Outstanding 42.19
BGMD's Days Sales Outstanding is ranked higher than
78% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.75 vs. BGMD: 42.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
BGMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.95  Med: 42.19 Max: 350.29
Current: 42.19
11.95
350.29
Days Payable 402.51
BGMD's Days Payable is ranked higher than
92% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.55 vs. BGMD: 402.51 )
Ranked among companies with meaningful Days Payable only.
BGMD' s Days Payable Range Over the Past 10 Years
Min: 44.46  Med: 276.26 Max: 640.84
Current: 402.51
44.46
640.84

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.12
BGMD's Price/Median PS Value is ranked higher than
94% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. BGMD: 0.12 )
Ranked among companies with meaningful Price/Median PS Value only.
BGMD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.74 Max: 4.52
Current: 0.12
0.23
4.52
Earnings Yield (Greenblatt) (%) -666.70
BGMD's Earnings Yield (Greenblatt) (%) is ranked lower than
100% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. BGMD: -666.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BGMD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3319.36  Med: 518.40 Max: 12440.4
Current: -666.7
-3319.36
12440.4

More Statistics

Revenue (TTM) (Mil) $1.57
EPS (TTM) $ -0.72
Beta1.35
Short Percentage of Float10.14%
52-Week Range $0.17 - 2.13
Shares Outstanding (Mil)11.37
» More Articles for OTCPK:BGMD

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
BG MEDICINE, INC. Financials Apr 08 2016
BG MEDICINE, INC. Files SEC form 10-K, Annual Report Apr 04 2016
BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events Mar 31 2016
BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 04 2016
BG MEDICINE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 23 2015
BG MEDICINE, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... Dec 04 2015
BG MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Nov 30 2015
BG Medicine, Inc. Earnings Q3, 2015 Nov 27 2015
BG MEDICINE, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Nov 23 2015
BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Nov 20 2015
Edited Transcript of BGMD earnings conference call or presentation 17-Nov-15 1:30pm GMT Nov 17 2015
BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Nov 17 2015
BG MEDICINE, INC. Files SEC form 10-Q, Quarterly Report Nov 16 2015
BG Medicine Due Diligence Report: Quietly Making Headway - Broad Street Alerts Nov 05 2015
BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers Sep 25 2015
BG Medicine, Inc. Earnings Q2, 2015 Sep 17 2015
BG MEDICINE, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Sep 15 2015
5 Stocks Ready for Breakouts Aug 21 2015
Edited Transcript of BGMD earnings conference call or presentation 19-Aug-15 12:30pm GMT Aug 19 2015
BG MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to... Aug 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)